Asset
Bocodepsin Besylate
OnKure Therapeutics Inc. Class A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03931681 | phase1 | completed | 2019-05-08 | 2021-11-27 | OnKure, Inc. | A Study of OKI-179 in Patients With Solid Tumors |
| NCT05340621 | phase1_2 | completed | 2022-05-11 | 2025-01-29 | OnKure, Inc. | NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) |
FDA applications (0)
This company has no applications containing this asset.